Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554208 | 1.00 | CTSS (0.51) | CTSSCTSKL3MBTL1MEN1KMT2A | |
| SCHEMBL16566319 | 1.00 | CTSS (0.51) | CTSSCTSKL3MBTL1MEN1KMT2A | |
| SCHEMBL28267459 | 0.87 | MEN1 (0.50) | CTSSCTSKL3MBTL1MEN1KMT2A | |
| SCHEMBL19602353 | 0.87 | MEN1 (0.50) | CTSSCTSKL3MBTL1MEN1KMT2A | |
| SCHEMBL648574 | 0.86 | POLB (0.58) | CTSSCTSKL3MBTL1NTSR1POLB | |
| SCHEMBL7512116 | 0.86 | POLB (0.58) | CTSSCTSKL3MBTL1NTSR1POLB | |
| SCHEMBL1463134 | 0.86 | POLB (0.58) | CTSSCTSKL3MBTL1NTSR1POLB | |
| SCHEMBL19602659 | 0.86 | CTSS (0.48) | CTSSCTSKL3MBTL1MEN1KMT2A | |
| SCHEMBL28477083 | 0.85 | CTSK (0.47) | CTSSCTSKMEN1KMT2ATSHR | |
| SCHEMBL25340610 | 0.84 | CTSK (0.49) | CTSSCTSKL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-07-30 | — | — | US | disclosed |
| CN-111269264-A | Dioxolane analogues of uridine for the treatment of cancer | 美迪维尔公司 | 2020-06-12 | — | — | CN | disclosed |
| US-9540411-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-01-10 | — | — | US | disclosed |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| EP-3057976-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-08-24 | — | — | EP | disclosed |
| EP-3041855-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016030335-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2016-03-03 | — | — | WO | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | CTSS 4845/4885CTSK 4650/4885L3MBTL1 1286/4885 |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | CTSS 991/4885CTSK 1517/4885L3MBTL1 3522/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | CTSS 4845/4885CTSK 4719/4885L3MBTL1 1439/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | CTSS 991/4885CTSK 1517/4885L3MBTL1 3522/4885 |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | CTSS 991/4885CTSK 1517/4885L3MBTL1 3522/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | CTSS 4845/4885CTSK 4650/4885L3MBTL1 1286/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | CTSS 4845/4885CTSK 4650/4885L3MBTL1 1286/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | CTSS 4845/4885CTSK 4650/4885L3MBTL1 1286/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | CTSS 4845/4885CTSK 4650/4885L3MBTL1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.